新光药业 reported revenue of ¥0.14B for the period ended 2026-06-30, +1.2% year on year. Net income was ¥0.04B, a 27.8% net margin on a 46.1% gross margin. The largest revenue line is 黄芪生脉饮 at 73% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.14B | +1.2% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥0.05B | — |
| Net income | ¥0.04B | +24.5% |
| Gross margin | 46.1% | Net margin 27.8% |
| Revenue Q/Q | -38.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 黄芪生脉饮 | ¥0.10B | 72.6% |
| 西洋参口服液 | ¥0.03B | 17.5% |
| 伸筋丹胶囊 | ¥0.01B | 7.9% |
| 其他产品 | ¥0.00B | 1.9% |
| 其他(补充) | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.08B | 53.9% |
| R&D | ¥0.01B | 4.8% |
| SG&A | ¥0.02B | 11.7% |
| Tax & other | ¥0.01B | 4.0% |
| Item | Amount |
|---|---|
| Total assets | ¥0.88B |
| Total liabilities | ¥0.05B |
| Shareholders' equity | ¥0.83B |
| Equity / assets | 93.9% |
| Operating cash flow | ¥0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 145% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
科大国创 ・ 爱司凯 ・ 世名科技 ・ 辰安科技 ・ 博思软件 ・ ST应急 ・ 幸福蓝海 ・ 健帆生物 ・ 领湃科技 ・ 优博讯 ・ 今天国际 ・ 冰川网络
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies